GlaxoSmithKline: Colorectal Neoplasms trials
The registry lists 15 Colorectal Neoplasms studies with GlaxoSmithKline as lead sponsor. 4 are open to participants now and 4 have results posted.
Phase 1 13Phase 2 6Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursNot yet recruitingNCT07947134Phase 1/2
- A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsRecruitingNCT07277270Phase 1
- A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsRecruitingNCT07213609Phase 1/2
- A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)RecruitingNCT06885034Phase 1/2
- Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsCompletedNCT03250832Phase 1Results posted
- A Phase 1/2 Trial of SRA737 in Subjects With Advanced CancerCompletedNCT02797964Phase 1/2Results posted
- A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.CompletedNCT00601172Phase 3Results posted
- Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal CancerCompletedNCT00536809Phase 1Results posted
- A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsActive, not recruitingNCT06710847Phase 1/2
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingNCT05277051Phase 1
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1
- A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic MetastasesCompletedNCT00920803Phase 1
- Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal CancerCompletedNCT00540943Phase 1
- Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)CompletedNCT00387387Phase 1
- GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or OxaliplatinCompletedNCT00044343Phase 2